{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:28:57Z","timestamp":1783650537976,"version":"3.55.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Extramedullary disease is a manifestation of multiple myeloma, the prognosis of which remains poor even in the era of novel drugs. Therefore, we aimed to develop a predictive model for patients with primary extramedullary multiple myeloma (EMM).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Clinical and laboratory data of patients diagnosed with primary EMM between July 2007 and July 2021 were collected and analyzed. Univariate and least absolute shrinkage and selection operation Cox regression analyses (LASSO) were used to select prognostic factors for overall survival (OS) to establish a nomogram prognostic model. The performance of the model was evaluated using concordance index which was internally validated by bootstraps with 1,000 resample, area under the curve (AUCs), and calibration curves.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> 217 patients were included in this retrospective study. Patients with EMM had a higher rate of belonging to the male sex, age &amp;gt;50\u00a0years, advanced Durie\u2013Salmon stage III, hypercalcemia, and low hemoglobin level. Compared with patients with bone-related extramedullary disease, those with extraosseous-related extramedullary disease had a higher frequency of advanced Durie\u2013Salmon stage III, lower rate of hypercalcemia, and elevated prothrombin time. The OS and progression-free survival (PFS) of patients with bone-related extramedullary disease were significantly higher than those of patients with extraosseous-related extramedullary disease. After the univariate and LASSO analyses, six prognostic factors, including performance status, number of extramedullary involved sites, \u03b22-microglobulin, lactate dehydrogenase, monocyte\u2013lymphocyte ratio, and prothrombin time, were integrated to establish a nomogram. The model showed robust discrimination with a concordance index (C-index) of 0.775 (95% confidence interval [CI], 0.713\u20130.836), internally validated with the corrected C-index of 0.756, and excellent performance in time-dependent AUCs compared with other staging systems. The AUCs for 1-, 3-, and 5-year OS were 0.814, 0.744, and 0.832, respectively. The calibration curves exhibited good consistency between the observed and nomogram-predicted OS. The 5-year OS of patients in the high-risk group (23.3%; 95% CI, 13.9%\u201339.3%) was much worse than that in the low-risk group (73.0%; 95% CI, 62.5%\u201385.4%; <jats:italic>p<\/jats:italic> &amp;lt; 0.001).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The nomogram predictive model based on six clinical variables showed good prognostic performance and could better predict individual survival in patients with EMM.<\/jats:p>","DOI":"10.3389\/fcell.2022.1021587","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:09:20Z","timestamp":1669356560000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A prognostic model for patients with primary extramedullary multiple myeloma"],"prefix":"10.3389","volume":"10","author":[{"given":"Limei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weida","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s10147-017-1127-9","article-title":"Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection: Methodological issues","volume":"22","author":"Ayubi","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/s1470-2045(14)71116-7","article-title":"Nomograms in oncology: More than meets the eye","volume":"16","author":"Balachandran","year":"2015","journal-title":"Lancet. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4110\/in.2017.17.4.250","article-title":"Distinct clinical outcomes between paramedullary and extramedullary lesions in newly diagnosed multiple myeloma","volume":"17","author":"Batsukh","year":"2017","journal-title":"Immune Netw."},{"key":"B4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3324\/haematol.2019.219295","article-title":"A real world multicenter retrospective study on extramedullary disease from balkan myeloma study group and barcelona university: Analysis of parameters that improve outcome","volume":"105","author":"Beksac","year":"2020","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/jco.2014.55.7900","article-title":"Best treatment strategies in high-risk multiple myeloma: Navigating a gray area","volume":"32","author":"Bianchi","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ajh.25365","article-title":"Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma","volume":"94","author":"Binder","year":"2019","journal-title":"Am. J. Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: A systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/jco.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: Incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blad\u00e9","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/jco.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00277-021-04529-5","article-title":"Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma","volume":"100","author":"Cejalvo","year":"2021","journal-title":"Ann. Hematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/s2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK myeloma research alliance risk profile): A development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet. Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1634\/theoncologist.2019-0356","article-title":"CIC mutation as a molecular mechanism of acquired resistance to combined BRAF-MEK inhibition in extramedullary multiple myeloma with central nervous system involvement","volume":"25","author":"Da Vi\u00e0","year":"2020","journal-title":"Oncologist"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/s1470-2045(14)70263-3","article-title":"Cancer-related inflammation and treatment effectiveness","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1038\/bcj.2017.60","article-title":"Significance of the absolute lymphocyte\/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma","volume":"7","author":"Dosani","year":"2017","journal-title":"Blood Cancer J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3324\/haematol.2017.178434","article-title":"Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the chronic malignancies working party of the EBMT","volume":"103","author":"Gagelmann","year":"2018","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/cncr.26447","article-title":"Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients","volume":"118","author":"Gozzetti","year":"2012","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/jco.2007.12.9791","article-title":"How to build and interpret a nomogram for cancer prognosis","volume":"26","author":"Iasonos","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study","volume":"31","author":"Kumar","year":"","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/bmt.2017.165","article-title":"Multiple myeloma with extramedullary disease: Impact of autologous stem cell transplantation on outcome","volume":"52","author":"Kumar","year":"","journal-title":"Bone Marrow Transpl."},{"key":"B23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"B24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00277-014-2216-8","article-title":"Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma","volume":"94","author":"Lee","year":"2015","journal-title":"Ann. Hematol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"6681521","DOI":"10.1155\/2021\/6681521","article-title":"Clinical characteristics and prognostic analysis of multiple myeloma with extramedullary disease: A SEER-based study","volume":"2021","author":"Li","year":"2021","journal-title":"J. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3109\/10428194.2013.853296","article-title":"Autologous stem cell transplant can overcome poor prognosis in patients with multiple myeloma with extramedullary plasmacytoma","volume":"55","author":"Li","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"B27","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1200\/jco.2014.56.6661","article-title":"Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer","volume":"33","author":"Liang","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/sj.bmt.1705982","article-title":"Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome","volume":"41","author":"Minnema","year":"2008","journal-title":"Bone Marrow Transpl."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/sj.leu.2404085","article-title":"Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients","volume":"20","author":"P\u00e9rez-Sim\u00f3n","year":"2006","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2013.094409","article-title":"Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse","volume":"99","author":"Pour","year":"2014","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41408-017-0019-6","article-title":"The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents","volume":"7","author":"Romano","year":"2017","journal-title":"Blood Cancer J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00277-015-2462-4","article-title":"Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents","volume":"94","author":"Romano","year":"2015","journal-title":"Ann. Hematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"djv291","DOI":"10.1093\/jnci\/djv291","article-title":"Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma","volume":"108","author":"Tang","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"B35","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","article-title":"How I treat extramedullary myeloma","volume":"127","author":"Touzeau","year":"2016","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/s0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: A longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3109\/10428194.2012.740562","article-title":"Extramedullary multiple myeloma","volume":"54","author":"Weinstock","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"B40","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2022.1021587\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:09:22Z","timestamp":1669356562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2022.1021587\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":40,"alternative-id":["10.3389\/fcell.2022.1021587"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2022.1021587","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,25]]},"article-number":"1021587"}}